key: cord-1023658-r2ezdtmb
authors: Dhumal, Sachin; Patil, Amar; More, Ashwini; Kamtalwar, Sujeet; Joshi, Amit; Gokarn, Anant; Mirgh, Sumeet; Thatikonda, Puneeth; Bhat, Prasanth; Murthy, Vedang; Chavan, Preeti; Oak, Amey; Gore, Suvarna; Bhattacharjee, Atanu; Patkar, Nikhil; Kannan, Sadhana; Shetty, Nitin; Rawat, Anjali; Achrekar, Meera; Trivedi, Bhakti; Laskar, Siddhartha; Chaturvedi, Pankaj; Badwe, Rajendra; Khattry, Navin; Gupta, Sudeep
title: SARS-COV-2 reinfection after previous infection and vaccine breakthrough infection through the second wave of pandemic in India: An observational study
date: 2022-02-19
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2022.02.037
sha: 33f75d6feb87830a518a1dba24a83ee0d62fb36a
doc_id: 1023658
cord_uid: r2ezdtmb

Background : There is sparse longitudinal data on SARS-CoV-2 infection after previous infection and after partial or full vaccination. Methods : This study in a cohort of healthcare workers used Kaplan-Meier analysis with appropriate definition of events and censoring and Cox models to assess outcomes, with data cut-off on June 18, 2021. Results : A total of 1806 individuals with median age of 32 (18-64) years, 1483 (82.1%) with at least one vaccine dose, 1085 (60.1%) with two vaccine doses, 408 (22.6%) with at least one episode of SARS-CoV-2 infection and 6 (1.47%) with two episodes of infection, were included in the analysis. At median follow-up of 38.4 weeks after first SARS-CoV-2 (n=408), the 52-week probability of reinfection was 2.2% (95%CI, 1.0-4.91%) and at median follow-up of 13.3 weeks after second dose, 16-week probability of breakthrough infection was 5.6% (95%CI, 4.33-7.23%), which was significantly higher among those without prior SARS-CoV-2 infection versus with prior infection (6.4% vs 1.8%, p=0.016, adjusted Cox HR=3.49, 95%CI, 1.09-11.20, p=0.036) and females versus males (7.9% vs 3.8%, p=0.007, adjusted Cox HR=2.06, 95%CI, 1.19-3.56, p=0.01). Conclusions : There was low probability of reinfection after prior SARS-CoV-2 infection, and higher vaccine breakthrough infections among females and those without prior infection.

There is sparse longitudinal data on SARS-CoV-2 infection after previous infection and after partial or full vaccination.

This study in a cohort of healthcare workers used Kaplan-Meier analysis with appropriate definition of events and censoring and Cox models to assess outcomes, with data cut-off on June 18, 2021.

A total of 1806 individuals with median age of 32 (18-64) years, 1483 (82.1%) with at least one vaccine dose, 1085 (60.1%) with two vaccine doses, 408 (22.6%) with at least one episode of SARS-CoV-2 infection and 6 (1.47%) with two episodes of infection, were included in the analysis. At median follow-up of 38.4 weeks after first SARS-CoV-2 (n=408), the 52-week probability of reinfection was 2.2% (95%CI, 1.0-4.91%) and at median follow-up of 13.3 weeks after second dose, 16-week probability of breakthrough infection was 5.6% (95%CI, 4.33-7.23%), which was significantly higher among those without prior SARS-CoV-2 infection versus with prior infection (6.4% vs 1. 8%, p=0.016, adjusted Cox HR=3.49, 95%CI, p=0 .036) and females versus males (7.9% vs 3.8%, p=0.007, adjusted Cox HR=2.06, 95%CI, 1.19-3.56, p=0.01).

There was low probability of reinfection after prior SARS-CoV-2 infection, and higher vaccine breakthrough infections among females and those without prior infection.

The coronavirus disease 2019 (Covid-19) pandemic will shortly complete two years since it was first discovered but there is continuing uncertainty about several aspects of this disease.

One of the most important questions is the degree and duration of protective immunity by an episode of infection with its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Kim et Several health care institutions, including ours, continued to provide medical care throughout the course of the pandemic. Health care workers and other employees of such institutions experienced SARS-CoV-2 infection at variable rates that largely mirrored the ebb and flow of the pandemic in the community. Moreover, workers in health care institutions were among the first to receive vaccination against this disease when it became available. Thus, evaluation of SARS-CoV-2 infection data among health care institutional employees provides valuable opportunity for longitudinal evaluation of protective immunity due to previous infection and/or vaccination. There are currently sparse data on vaccine breakthrough infections (Bergwerk et al., 2021 , Tareq et al., 2021 We conducted a retrospective, non-interventional, longitudinal study among employees of a single large tertiary cancer centre in India to study the incidence of SARS-CoV-2 reinfection (after a previous infection) and vaccine breakthrough infection, during a period that spanned the occurrence of first and second waves of pandemic in India.

This retrospective observational study was conducted to assess the longitudinal incidence of laboratory confirmed SARS-CoV-2 infection among all health care workers in our institution in relation to previous episodes of infection and receipt of a SARS-CoV-2 vaccine. The study was approved by the Institutional Ethics Committee prior to its initiation and is registered in the Clinical Trials Registry of India (CTRI/2021/08/035655). Informed consent was waived by the Ethics Committee for subjects whose data could be entirely abstracted from the electronic medical record (EMR). However, for those subjects whose complete data was not available on EMR, the Ethics Committee approved telephonic contact and telephonic collection of data after obtaining an approved format of telephonic consent. Of the 1806 subjects included in the study, some data was collected through telephone contact after obtaining telephonic consent, from 329 individuals.

Data was collected from the electronic medical records of the institution and its ongoing vaccination program and entered into an electronic database. The eligibility criterion for inclusion in the study was all employees of the institution in permanent or temporary employment as on the date of start of pandemic in India. Information on age, sex, dates of first and second doses of vaccine, type of vaccine, date of occurrence of laboratory confirmed SARS-CoV-2 infection, requirement for hospitalization, number of days of hospitalization, and need for oxygen administration was extracted from the medical records.

Vaccination was given according to Government of India guidelines which were modified from time to time. The ChAdOx1 nCoV-2 vaccine was given initially (January 2021 to March 2021) with an interval of 4-6 weeks between the first and second dose, an interval of 6-8 weeks from April 2021 to May 12, 2021, and an interval of 12-16 weeks from May 13, 2021 onwards, based on evolving data (Voysey M, at al., 2021) . The BBV-152 vaccine was given at an interval of 4-6 weeks throughout the study period.

The Kaplan-Meier method was used to compute the probability of SARS-CoV-2 infection in each subgroup of interest, with appropriate definition of left and right time boundaries, events and censoring. The Cox proportional hazards method was used for multivariable analysis of impact of covariates on the probability of SARS-CoV-2 infection. Time-dependent covariates were used to test the proportional hazards assumption and an appropriate time-interaction term was entered in the model if this assumption was not met. The period of risk was assumed to start on the date of first lockdown in India on March 24, 2020 and the data cut-off date was June 18, 2021. The following analyses were performed.

The cumulative probability of developing SARS-COV-2 among all healthcare workers since the beginning of pandemic in India (March 24, 2020) until the receipt of first vaccine dose was assessed in the entire employee cohort. The diagnosis of laboratory confirmed SARS-CoV-2 infection prior to date of first vaccine dose in those who received a vaccine or prior to the cut-off date in unvaccinated individuals, constituted an event for this analysis. Those who did not develop SARS-CoV-2 infection were censored on the date of first vaccine dose (if vaccinated) or on data cut-off date (if not vaccinated). Those who died without experiencing the event were also censored on the date of death.

We evaluated the incidence of laboratory-confirmed SARS-CoV-2 reinfection after a prior episode of SARS-CoV-2 infection. Reinfection was defined as RT-PCR positivity for SARS-COV-2 at least 8 weeks after the date of known RT-PCR negativity after first infection or, if RT-PCR negativity after prior infection was not documented, at least 8 weeks from the date of joining work after previous infection. The left time boundary for this analysis was assumed to start on the date of laboratory diagnosis of the first episode of SARS-CoV-2 infection and an event was defined as diagnosis of a second episode of laboratory confirmed SARS-CoV-2 infection. Employees with one episode of infection, who did not develop a second infection were censored on the data cut-off date.

The cumulative probability of SARS-CoV-2 was evaluated among employees after receiving first dose and prior to receiving second dose of vaccine. The left time boundary for this analysis was assumed to start on the date of first vaccine dose and an event was defined as diagnosis of laboratory confirmed SARS-CoV-2 infection after the first vaccine dose and prior to the second vaccine dose. Those who did not develop SARS-CoV-2 infection were censored on the date of second vaccine dose (if they received second dose) or on data cut-off date (if they did not receive second dose).

The cumulative probability of SARS-CoV-2 was evaluated among employees after second dose of vaccine. The left time boundary for this analysis was assumed to start on the date of second vaccine dose and an event was defined as diagnosis of laboratory confirmed SARS-CoV-2 infection after the second vaccine dose and prior to the cut-off date. Those who did not develop SARS-CoV-2 infection after second vaccine dose were censored on the cut-off date.

The analysis was performed using the SPSS Version 24 statistical software. A total of 408 (22.6%) employees developed at least one episode of SARS-CoV-2 infection, of whom 6 (1.47%) developed reinfection, 332 (18.4%) developed SARS-CoV-2 prior to vaccination, 25 (1.4%) after first vaccine dose and prior to second vaccine dose, and 56

(3.1%) after the second dose. Of those who developed SARS-CoV-2 infection, 126 (30.9%) required hospitalization for any reason, with a median of 8 (1-35) days of hospitalization. Of those who were hospitalized, 12 (9.5%) required oxygen administration and there was one death due to Covid-19 (Table 1) .

The denominator for this analysis was all employees of the institution (N=1806). At a median follow-up of 64.4 weeks, the cumulative actuarial probability of SARS-CoV-2 infection was 22.6% (95% CI, 20.73-24.59%) (Figure 1 ).

The denominator for this analysis was all employees of the institution (N=1806). At a median follow-up of 47.4 (0-64.4) weeks, the 60-week cumulative actuarial probability of SARS-CoV-2 infection was 22.3% (95% CI, 19.95-24.95%) (Figure 2A) . On univariable analysis, there was no significant difference in the 60-week probability of infection between males and females (22.7% vs 21.9%, p=0.32) (Figure 2B) , and between older (>/= 50 years) and younger (<50 years) employees (21.6% vs 22.4%, p=0.50) ( Figure 2C ). In multivariable Cox regression analysis including sex, age (as a continuous variable) and their respective time-interaction terms, it was found that the proportional hazards assumption was not met for both sex and age. After adjusting for each other and their time-interaction terms, females had a significantly lower probability of SARS-CoV-2 infection prior to vaccination compared with males (HR=0.494; 95% CI, 0.274-0.892; p=0.019), while older employees had a significantly higher probability of this infection (HR=1.041; 95% CI, 1.008-1.075; p=0.013) ( Table 2) .

The denominator for this analysis were all employees who developed at least one episode of laboratory confirmed SARS-CoV-2 infection (n=408). At a median follow-up of 38.4 (7.1-55.0) weeks after first infection, the 52-week cumulative actuarial probability of SARS-CoV-2 infection was 2.2% (95% CI, 1.0-4.91%) (Figure 3 ).

The denominator for this analysis were all employees who received at least one dose of recombinant ChAdOx1 nCoV-19 CoronaVirus Vaccine or whole-virion inactivated vaccine (BBV152) (n=1458). At a median follow-up of 5.3 (0-20.9) weeks, the 20-week cumulative actuarial probability of SARS-CoV-2 infection after first and prior to the second vaccine dose was 2.7% (95% CI, 1.78-4.16%) ( Figure 4A ). Among those who experienced the event for this analysis (n=25), the median time to SARS-CoV-2 infection after first vaccine dose was 3.86 weeks. In univariable analysis the probability of infection after first vaccine dose was not significantly different between employees who had prior SARS-CoV-2 infection compared with those without prior SARS-CoV-2 infection (20-week cumulative probability 0.4% vs 3.2%, p=0.08) ( Figure 4B ).

The denominator for this analysis were all employees who received two doses of recombinant ChAdOx1 nCoV-19 CoronaVirus Vaccine or whole-virion inactivated vaccine (BBV152) (n=1085). At a median follow-up of 13.3 (0-16.6) weeks, the 16-week cumulative actuarial probability of SARS-CoV-2 infection after second vaccine dose was 5.6% (95% CI, 4.33-7.23%) ( Figure 5A ). Among those who experienced the event for this analysis (n=56), the median time to SARS-CoV-2 infection after second vaccine dose was 4.1 weeks. In univariable analysis, the probability of infection after second vaccine dose was significantly lower among males compared with females (16-week cumulative probability 3.8% vs 7.9%, p=0.007) ( Figure 5B ) and in those with prior SARS-CoV-2 infection compared with those without prior SARS-CoV-2 infection (16-week cumulative probability 1.8% vs 6.4%, p=0.016) ( Figure 5C ), but there was no significant difference between older (>/= 50 years) and younger employees (16-week cumulative probability 3.9% vs 5.7%, p=0.55) ( Figure   5D ). In multivariable Cox analysis the proportional hazards assumption was met for all covariates. In this model, female sex (HR=2.06; 95% CI, 1.19-3.56; p=0.01) and lack of prior SARS-CoV-2 infection (HR=3.49; 95% CI, 1.09-11.20; p=0.036) were associated with significantly higher probability of infection after second vaccine dose, but there was no significant association with age (continuous variable) (HR=1.01; 95% CI, 0.98-1.04; p=0.419) ( Table 2) . A sensitivity analysis was performed after excluding those who developed SARS-CoV-2 infection within 14 days of receiving the second vaccine dose (n=8) and counting the period of risk after 14 days of second vaccine dose. This did not change the results and in the multivariable Cox model, female sex and lack of prior SARS-CoV-2 infection continued to be significantly associated with higher risk of infection (data not shown).

The results of this retrospective longitudinal analysis in health care workers suggest that the first episode of SARS-CoV-2 infection provides strong protection against reinfection, which lasts for at least a year, including during periods of high transmission in the community.

Vaccination with ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant) also provides protective immunity, albeit weaker than that by natural infection, and prior infection with SARS-CoV-2 adds to the protection provided by vaccination. These results provide quantitative estimates of probabilities of reinfections and vaccine breakthrough infections, which would be useful to epidemiologists in modelling the future course of the pandemic.

They would also be useful to hospital administrations, especially cancer centres, in human resource planning during the ongoing pandemic. Interestingly, Figure 1 shows a 'stepwise' increase in the incidence of SARS-CoV-2 infection in essentially two steps. Since the data for entire cohort started on day 0, the 'first step' (from week 12 to week 26) corresponds to the period between mid-June 2020 and end-September 2020 (first 'wave' in India) and the 'second step' (from week 51 to week 58) corresponds to the period between mid-March 2021 and early-May 2021 (second 'wave' in India). The second wave seems to be weaker than the first wave among our study cohort, contrary to the pattern in Indian population. In Figure 2A , week 43 (mid-January 2021) corresponds to the start of vaccination program in India and which was limited to only healthcare and other frontline workers until March 2021, after which it was rolled out for the general population.

Therefore, it is likely that the attenuated second wave in our study cohort was attributable to vaccination of some of our employees prior to the onset of second wave in India.

The overwhelming majority of individuals in this cohort received the recombinant ChAdOx1 nCoV-19 Corona Virus Vaccine. The cumulative probabilities of SARS-CoV-2 infection after first and second vaccine doses of 2.7% and 5.6%, respectively, within relatively short follow-up durations, suggest weaker protection by vaccination compared to natural infection.

The incidence of vaccine breakthrough infections was significantly lower among employees who had prior SARS-CoV-2 infection attesting to the substantial protection provided by natural infection, a result that has also been reported by others (Gazit S, et al., 2021) . The incidence of SARS-CoV-2 after prior COVID and one vaccine dose was 0.4% whereas the incidence of SARS-CoV-2 infection without prior COVID but after two vaccine doses was 6.4%. This suggests that individuals with previous infection likely develop similar or even higher levels of antibody and possibly non-antibody immunity compared with those without prior COVID after two vaccine doses (Perkmann T, et al, 2021).

The incidence of SARS-CoV-2 infection in unvaccinated females was significantly lower compared with unvaccinated males, but the incidence of vaccine breakthrough infections was significantly higher in females compared with males, for unclear reasons. Higher breakthrough infections in females has also been reported by others (Birhane M, et al., 2021 , Vaishya et al., 2021 , although the underlying mechanisms remain obscure. We did not collect information about other factors such as profession, social interaction pattern, use of public versus private transport at various time periods of the pandemic, etc. that could potentially clarify this result. The genetic characterization of SARS-CoV-2 which were responsible for vaccine breakthrough infections in this cohort is being reported in a separate manuscript but the large majority were due to the delta (B.1.617.2) variant. This analysis has several strengths. There was complete follow-up information on the entire study population with no loss of longitudinal information. The analysis period spanned both waves of the pandemic in India with results that are contemporaneous and relevant. The diagnosis of SARS-CoV-2 infection was performed by reliable within institution testing by the reverse transcriptasepolymerase chain reaction (RT-PCR) method. We have used the time-to-event Kaplan-Meier method for estimating the risk of reinfection and vaccine breakthrough infection which does not discard any data.

The analysis also has some weaknesses. The predisposition to SARS-CoV-2 infection involves many variables, including COVID appropriate behaviour, which were uncontrolled in this analysis. The period of follow-up, especially after vaccination, is short and therefore the estimates of breakthrough infections might change with further follow-up. Systematically collected data on immunological variables, including serum neutralizing antibodies, were not available.

We chose not to set a time-limit of 14 days after the second vaccine dose for characterizing breakthrough infections because our primary aim was to report the incidence of such infections in a real world setting rather than correlate them with immunological status of the subjects.

In conclusion, this analysis suggests that previous natural SARS-CoV-2 infection provides substantial protection against reinfection. Previous infection adds to the protection offered by vaccination and females experience higher incidence of vaccine breakthrough infections. 

Antibody Responses to Natural SARS-CoV-2 Infection or after COVID-19

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Breakthrough Infections in Vaccinated Health Care Workers

COVID-19 Vaccine Breakthrough Infections Reported to CDC -United States

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a doubleblind, randomised phase 1 trial

Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections

A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity

The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection

Will SARS-CoV-2 Infection Elicit Long-Lasting Protective or Sterilising Immunity? Implications for Vaccine Strategies (2020)

Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study

Serum antibody response to BNT162b2 after natural SARS-CoV-2 infection

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Impact of SARS-CoV-2 delta variant (B.1.617.2) in surging second wave of COVID-19 and efficacy of vaccines in tackling the ongoing pandemic

Predominance of delta variant among the COVID-19 vaccinated and unvaccinated individuals

SARS-CoV-2 infection after COVID-19 immunization in healthcare workers: A retrospective, pilot study

Singledose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

We acknowledge the efforts of all healthcare workers of our institution who continued to provide services to patients throughout the period of pandemic.

No author reports any conflict of interest